TransMolecular receives FDA approval for 131-I-TM-601 IND application.
D000328:Adult; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use; D017277:Drug Approval / Q000331:legislation & jurisprudence* / Q000379:methods; D004345:Drug Industry / Q000331:legislation & jurisprudence* / Q000379:methods; D015507:Drugs, Investigational / Q000627:therapeutic use*; D005910:Glioma / Q000188:drug therapy; D006801:Humans; D012604:Scorpion Venoms / Q000737:chemistry / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D012604:Scorpion Venoms; C091539:Chlorotoxin